This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
KalVista Pharmaceuticals 향후 성장
Future 기준 점검 5/6
KalVista Pharmaceuticals은 연간 수입과 매출이 각각 60.3%와 27.5% 증가할 것으로 예상되고 EPS는 연간 57.2%만큼 증가할 것으로 예상됩니다.
핵심 정보
60.3%
이익 성장률
57.19%
EPS 성장률
| Biotechs 이익 성장 | 24.6% |
| 매출 성장률 | 27.5% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 11 Jun 2026 |
최근 향후 성장 업데이트
Recent updates
Seeking Alpha • Apr 29
KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome
Summary KalVista Pharmaceuticals, Inc. is being acquired by Chiesi Group for $27/share in cash, valuing the company at $1.9 billion. KALV maintains a Strong Buy rating, driven by EKTERLY's $49.1M in 2025 sales and positive pediatric phase 3 KONFIDENT-KID interim results. EKTERLY is the first and only oral on-demand HAE therapy, with expansion into pediatric patients and multiple global markets underway. Key KALV risks include sNDA approval uncertainty for pediatric use, sustainability of EKTERLY sales, and successful Chiesi deal closure. Read the full article on Seeking Alpha
새로운 내러티브 • Jan 23
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals develops oral therapies for hereditary angioedema, including EKTERLY for on demand treatment of HAE attacks. What are the underlying business or industry changes driving this perspective?분석 기사 • Jan 10
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Sep 05
Is KalVista Pharmaceuticals (NASDAQ:KALV) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jul 09
Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Apr 02
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Dec 18
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
Summary NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. The company has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of 2027. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
KalVista: Upcoming PDUFA, But Not Without Risks
Summary KalVista's lead candidate, sebetralstat, has shown strong phase 3 results for on-demand treatment of HAE, with a PDUFA date set for June 17, 2025. Sebetralstat offers rapid symptom relief for acute HAE attacks, differentiating it from long-acting treatments like Navenibart and prophylactic options like Berotralstat. Financial concerns include a limited cash runway of three quarters, necessitating potential dilution for commercialization efforts post-approval. Despite promising data, competition from gene therapies and the shift towards prophylactic treatments make me cautious about investing in KalVista now. Read the full article on Seeking Alpha분석 기사 • Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 05
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Summary KalVista Pharmaceuticals, Inc. is advancing Sebetralstat, a potential first oral on-demand treatment for hereditary angioedema, with FDA approval expected in June 2025. Sebetralstat's successful Phase 3 trial and favorable safety profile position it to be a major player in the $900 million on-demand HAE market. Analysts are bullish on KalVista, with a recent Buy ratings and price targets ranging from $20 to $39 per share. KalVista has sufficient cash to fund operations into 2026, but may raise additional capital closer to the time around FDA approval. An analysis of KalVista Pharmaceuticals is presented in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 24
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Summary KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches. KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise. Sebetralstat could capture the $900 million on-demand HAE market and enhance its TAM to the $2.9 billion HAE market. Despite recent equity dilution, I believe KalVista's financials and regulatory progress make it a "buy" for new investors aware of biotech risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data for sebetralstat, with potential approval in early 2025. The financing of the commercialization of sebestralstat is still unclear, but KalVista now has many options for business development without diluting shareholders too much. The oral Factor XIIa product candidate is another interesting compound in indications with high unmet medical need that will be moved into clinic in 2024. Read the full article on Seeking Alpha분석 기사 • Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Oct 14
KalVista: Another Setback But The Key Value Driver Is Still In Place
Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the second half of 2023. Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. Although KalVista is funded beyond the next major milestones, the market does not attach value to the pipeline. KalVista once again shocks its shareholders with news regarding the termination of the KVD824 phase 2 trial. After its product candidate KVD001 failed to convince in a phase 2 study due to insufficient effectiveness a few years ago, safety concerns are the reason for the termination of the KVD824 trial. The news was very badly received by the market and, as a result, KalVista has lost more than 85% of its value since its peak following positive data on its product candidate Sebetralstat in 2021. Since Sebetralstat is apparently the main value driver of KalVista, and the developments in the pipeline do not allow any conclusions to be drawn about the latter, I wonder whether the high decline in the market capitalization of KalVista is justified. For me, the key value driver is still in place, meaning KalVista is significantly undervalued at current levels. In the following article, I want to introduce the company, explain my investment thesis and justify the potential of the value driver Sebetralstat. Business Of KalVista Pharmaceuticals KalVista (KALV) is a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing oral therapies for the rare disease hereditary angioedema ((HAE)). KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. HAE is a rare and potentially life-threatening disease, and despite the fact that there are several approved therapies, there is a high unmet medical need to improve the quality of life and ease of disease control. KalVista went public in 2016 through a reverse merger with Carbylan Therapeutics and raised $78.2 million at $17 per share in its first public offering in 2018. The Pipeline Looks Bigger Than It Is The origin of KalVista's pipeline lies in the deep understanding of plasma kallikrein inhibitors. Prior to the change in strategy to focus on developing therapies for HAE, the molecules were also being investigated for diseases in diabetic macular edema ((DME)). In summary, however, KalVista's research efforts have not been very successful in the past. Investors should currently focus on KalVista's lead product candidate, Sebetralstat, formerly known as KVD900, which is currently being investigated in a placebo-controlled Phase 3 trial as an on-demand therapy for HAE attacks. The results of the study are expected to be published in the second half of 2023 which, if positive, will form the foundation for a regulatory submission in the first half of 2024. Since there is already very strong and meaningful data from the Phase 2 trial, I think it is very likely that the success can be duplicated in the Phase 3 trial. The Phase 2 study in 53 HAE patients demonstrated with statistical significance both the clinical efficacy across all primary and secondary endpoints and the overall safety profile of Sebetralstat. The factor XIIa program clearly has great potential, but is still in preclinical development and investors should not assign a value to it at this time. In 2023, KalVista plans to file an investigational new drug application ((IND)) to move the program into human clinical trials. The factor XIIa program has tremendous potential in the prophylactic treatment of HAE. It targets an enzyme that plays a key role in HAE and could block the underlying cause of HAE attacks. If successful in a proof-of-concept study, the program could be expanded in other large market opportunities in the area of inflammation and thrombosis. Overview of Kalvista's pipeline (Company Presentation) KVD824 was investigated in a Phase 2 study for the prophylactic treatment of HAE. However, KalVista has terminated the study due to safety concerns, which indicate that KVD824 will no longer meet the requirements for a best-in-class oral prophylactic therapy. In the beginning, the DME program with its product candidate KVD001 generated a great deal of interest and resulted in a collaboration with Merck (MRK). Following disappointing Phase 2 data in which the primary endpoint was missed, Merck did not extend the collaboration. However, as a dose-dependent clinical benefit on vision has been observed in certain patients, KalVista is still evaluating how to proceed with KVD001. Financial Situation Following the last capital raise following the publication of the Phase 2 data of Sebetralstat at a price of $36 per share, KalVista is currently in a good financial position. With $142 million in cash and a cash runaway until at least 2024, KalVista is funded across key milestones and significant value drivers. With the recently announced termination of the KVD824 Phase 2 trial, an additional $3 million in research and development costs can be saved on a quarterly basis. In my opinion, investors should not fear dilution, as current prices do not reflect the value of Sebetralstat in any way. Nevertheless, I would like to mention that KalVista has access to an ATM with Cantor Fitzgerald, and can issue shares in the amount of $100 million. However, I expect a funding effort with the publication of Phase 3 topline data in the second half of 2023. At current prices, KalVista has a negative pipeline value of approximately $18 million. Consequently, despite the good Phase 2 trial results and the independence to KVD824, investors do not believe that Sebetralstat will be successful. KalVista is currently very attractively valued (Author's Chart) Investment Thesis An investor should always be clear on the reasons for investing in a company. Therefore, I will present my reasons why I believe KalVista is an attractive investment at current prices. KalVista currently has a negative pipeline value even though its lead product candidate is being investigated in a Phase 3 trial in an attractive orphan indication with high unmet medical need. In my opinion, an investment in KalVista given a negative pipeline value is a good opportunity to speculate on a data run in the second half of 2023. The HAE market is very attractive and KalVista has the opportunity to take market share from the established players with a differentiated and more convenient mechanism of action. Personally, I expect KalVista to reach a positive pipeline value of at least $200 million before data readout, which equates to at least $10 per share. Although much higher prices are certainly possible with positive data, I would like to limit my investment thesis to the data run at this time and reduce risk prior to the data release. The release of the data represents a binary event and carries tremendous risk. Even though the peer comparison below does not allow a complete comparison, one can still conclude that KalVista is undervalued based on current share prices. BioCryst (BCRX), with its approved oral drug for the prophylactic treatment of HAE, is a good example of KalVista's potential pathway with positive data. Even Astria (ATXS), which still owes proof-of-concept, currently has a higher pipeline valuation than KalVista. However, it should be noted that Astria is about to publish Phase 2 data, while KalVista has no catalysts scheduled for the next 12 months. Comparison of companies with oral HAE therapies. (Author's Chart) Market Outlook In HAE And Potential of Sebetralstat Having made my investment thesis clear, I want to justify why I attribute substantial value to Sebetralstat. The current standard of care provides both on-demand and preventive treatments. Overall, 6000-8000 patients are affected in the US and up to 15,000 patients in Europe, which translates into up to 100,000 annual attacks in the US and 150,000 in Europe. According to forecasts, the HAE market will show tremendous growth in the coming years, reaching 4.5 billion in 2027. The market will focus more and more on the prophylactic treatment, nevertheless patients will always need a back-up solution in case of an attack. Global HAE Treatment Market is Substantial and Growing (Astria Company Presentation) Currently, there are a number of approved products for HAE patients. The largest player in the HAE market is Takeda (TAK) with its product Takhzyro, which is administered subcutaneously every two weeks for prophylactic treatment. For on-demand treatment of HAE, Takeda offers Firazyr and Kalbitor as subcutaneous injections, generating in total approximately 50% of sales in the HAE market. Overall, the HAE market is very competitive and new product candidates are attracting very high interest. For example, in 2015, Shire (now Takeda) bought Dyax and its product candidate Takhzyro for $5.9 billion after robust Phase 1b data. HAE is a Meaningful and Growing Global Market (Pharvaris Company Presentation) Despite the large number of approved therapies, the HAE market continues to have a high unmet medical need. Except for the oral prophyhlactic drug Orladeyo, all therapies are administered by injection, which is generally less convenient for patients and reduces patient compliance. Injections present a hurdle for patients because, despite their effectiveness, they can cause pain at the injection site, are time-consuming to administer, and are difficult to store. All approved on-demand options have significant shortcomings. Early treatment improves outcomes but undertreatment and late treatment are common. Source: KalVista The barrier of using injections is also shown by studies. These show that less than 40% of all treated attacks are dosed within the first hour, and up to 45% of attacks weren't treated at all. These numbers prove that patients want new medicines that deliver on all fronts. People Living with HAE Desire HAE Therapy that can Deliver on ALL Fronts (Pharvaris Company Presentation) KalVista believes that its oral product candidate, Sebetralstat, has the potential to change the treatment paradigm for this disease. People living with HAE actively seek new products that demonstrate improvements in efficacy, safety and tolerability, and convenience. In addition, research with patient physicians and payers indicate that the drug profile of Sebetralstat could meet these requirements in case of positive study results. As a result, 93% of all patients said they could imagine switching to the oral product candidate Sebetralstat if approved. The benefits of Sebetralstat arise mainly from the fact that the drug is taken earlier due to the lower barriers. Patients should take the drug at the first sign of symptoms. Combined with the rapid uptake of the drug, Sebetralstat has the potential to stop the development of an attack at an early stage while symptoms are still mild and swelling is not severe. Early treatment of attacks leads to better overall disease management and prevention of attacks reaching the critical stage of significant swelling and discomfort. We therefore believe that a safe, oral on-demand treatment has the potential to become a preferred alternative for patients currently using injectable treatments. Source: KalVista분석 기사 • Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 08
KalVista Pharmaceticals GAAP EPS of -$0.94
KalVista Pharmaceticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$0.94. Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.Seeking Alpha • Aug 22
KalVista reaches five-month high as rival tumbles on hereditary angioedema
The shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached the highest level since March on Monday after Pharvaris N.V. (PHVS), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121. An oral bradykinin B2-receptor antagonist, PHA121, is undergoing U.S. clinical studies in HAE under two Investigational New Drug (IND) applications for the rare inherited blood disorder. KalVista (KALV) is also advancing KVD900, its oral therapy for HAE, in a global late-stage trial with data expected in H2 2023. Even if PHVS resolves its clinical hold on its HAE candidate, the event will continue to be an overhang to a certain extent and “position KALV well if clinical data next year play out as we hope,” Stifel analyst Paul Matteis, who has a Buy rating and $32 on KALV wrote. Read: In April, Japanese pharma giant Takeda (TAK), a market leader in HAE, launched its Takhzyro injection for the condition in the U.S.Seeking Alpha • Jul 07
KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
KalVista Pharmaceticals press release (NASDAQ:KALV): Q4 GAAP EPS of -$0.98 beats by $0.11. Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal year is primarily due to increased operating expenses. “We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are meeting our enrollment targets for both our current clinical trials, the sebetralstat KONFIDENT Phase 3 and KVD824 KOMPLETE Phase 2. In addition, we are making great strides in developing our next wave of investigational compounds with promising preclinical data for our oral Factor XIIa inhibitor program. The Company is also well-capitalized, with funding until at least early 2024, which we expect takes us beyond data from both of our ongoing clinical trials.”분석 기사 • May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 435 | 120 | 118 | 278 | 3 |
| 12/31/2027 | 348 | 44 | 60 | 153 | 5 |
| 12/31/2026 | 213 | -69 | -58 | -34 | 6 |
| 3/31/2026 | 114 | -136 | -92 | -89 | N/A |
| 12/31/2025 | 74 | -164 | -125 | -122 | N/A |
| 7/31/2025 | 1 | -203 | -168 | -167 | N/A |
| 4/30/2025 | N/A | -183 | -154 | -153 | N/A |
| 1/31/2025 | N/A | -176 | -128 | -128 | N/A |
| 10/31/2024 | N/A | -156 | -123 | -123 | N/A |
| 7/31/2024 | N/A | -142 | -103 | -103 | N/A |
| 4/30/2024 | N/A | -127 | -90 | -89 | N/A |
| 1/31/2024 | N/A | -108 | -97 | -97 | N/A |
| 10/31/2023 | N/A | -101 | -79 | -78 | N/A |
| 7/31/2023 | N/A | -95 | -80 | -79 | N/A |
| 4/30/2023 | N/A | -93 | -76 | -75 | N/A |
| 1/31/2023 | N/A | -91 | -81 | -79 | N/A |
| 10/31/2022 | N/A | -92 | -86 | -84 | N/A |
| 7/31/2022 | N/A | -89 | -85 | -83 | N/A |
| 4/30/2022 | N/A | -82 | -79 | -78 | N/A |
| 1/31/2022 | N/A | -73 | -63 | -62 | N/A |
| 10/31/2021 | N/A | -61 | -57 | -56 | N/A |
| 7/31/2021 | N/A | -52 | -45 | -44 | N/A |
| 4/30/2021 | N/A | -46 | -30 | -30 | N/A |
| 1/31/2021 | 4 | -38 | -32 | -32 | N/A |
| 10/31/2020 | 5 | -37 | -37 | -37 | N/A |
| 7/31/2020 | 9 | -33 | -37 | -37 | N/A |
| 4/30/2020 | 13 | -29 | -45 | -45 | N/A |
| 1/31/2020 | 12 | -31 | N/A | -43 | N/A |
| 10/31/2019 | 14 | -26 | N/A | -40 | N/A |
| 7/31/2019 | 16 | -23 | N/A | -41 | N/A |
| 4/30/2019 | 16 | -21 | N/A | -36 | N/A |
| 1/31/2019 | 18 | -13 | N/A | -32 | N/A |
| 10/31/2018 | 16 | -14 | N/A | 7 | N/A |
| 7/31/2018 | 12 | -16 | N/A | 9 | N/A |
| 4/30/2018 | 8 | -16 | N/A | 11 | N/A |
| 1/31/2018 | 4 | -19 | N/A | 14 | N/A |
| 10/31/2017 | 2 | -22 | N/A | -26 | N/A |
| 7/31/2017 | 1 | -21 | N/A | -23 | N/A |
| 4/30/2017 | 2 | -21 | N/A | -24 | N/A |
| 1/31/2017 | 2 | -23 | N/A | -23 | N/A |
| 10/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 7/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 4/30/2016 | 2 | -15 | N/A | -13 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: KALV 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.
수익 vs 시장: KALV (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: KALV 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: KALV 의 수익(연간 27.5%)이 US 시장(연간 12.6%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: KALV 의 수익(연간 27.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: KALV의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/12 23:19 |
| 종가 | 2026/06/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
KalVista Pharmaceuticals, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | BTIG |
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Maurice Raycroft | Jefferies LLC |